Overview
Michael Peyromaure practices in Paris, France. Mr. Peyromaure is rated as an Experienced expert by MediFind in the treatment of Superficial Thrombophlebitis. His top areas of expertise are Prostate Cancer, Mondor Disease, Non-Muscle Invasive Bladder Cancer, Prostatectomy, and Cystectomy.
His clinical research consists of co-authoring 159 peer reviewed articles. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Superficial Thrombophlebitis.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Advanced
- Mondor DiseaseMr. Peyromaure isAdvanced. Learn about Mondor Disease.
- Non-Muscle Invasive Bladder CancerMr. Peyromaure isAdvanced. Learn about Non-Muscle Invasive Bladder Cancer.
- Prostate CancerMr. Peyromaure isAdvanced. Learn about Prostate Cancer.
- ProstatectomyMr. Peyromaure isAdvanced. Learn about Prostatectomy.
- Experienced
- Bladder CancerMr. Peyromaure isExperienced. Learn about Bladder Cancer.
- CystectomyMr. Peyromaure isExperienced. Learn about Cystectomy.
- Enlarged Prostate (BPH)Mr. Peyromaure isExperienced. Learn about Enlarged Prostate (BPH).
- HydronephrosisMr. Peyromaure isExperienced. Learn about Hydronephrosis.
- HypercalcemiaMr. Peyromaure isExperienced. Learn about Hypercalcemia.
- Inflammatory Myofibroblastic TumorMr. Peyromaure isExperienced. Learn about Inflammatory Myofibroblastic Tumor.